Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study-Reference-Cited by-同舟云学术

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study

Author:

Gibiansky Ekaterina¹,Gibiansky Leonid¹,Buchheit Vincent²,Frey Nicolas²,Brewster Michael³,Fingerle‐Rowson Günter⁴,Jamois Candice²^ORCID

Affiliation:

1. QuantPharm LLC North Potomac MD USA

2. Pharma Research and Early DevelopmentRoche Innovation Center Basel Basel Switzerland

3. Clinical DevelopmentRoche Innovation Center Welwyn Welwyn Garden City UK

4. Pharma Development Clinical OncologyF. Hoffmann‐La Roche Ltd Basel Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

Reference54 articles.

1. Individualized management of follicular lymphoma;Bai B;Chin Clin Oncol,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献